ADMA BIOLOGICS INC (ADMA)
US0008991046 - Common Stock
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA’s Total Debt to $75 Million, a 29% Reduction ...
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Interesting ADMA Put And Call Options For August 2025
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET...
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...
Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors...
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
/PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc ("ADMA Biologics" or "the...
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
The company reiterated its outlook for 2024 and 2025.